Protocol 331-13-008: An Exploratory, Multicenter, Open-label, Flexible-dose Brexpiprazole (OPC-34712) Trial in Adults With Acute Schizophrenia

Trial Profile

Protocol 331-13-008: An Exploratory, Multicenter, Open-label, Flexible-dose Brexpiprazole (OPC-34712) Trial in Adults With Acute Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs Brexpiprazole (Primary) ; Aripiprazole
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 09 Mar 2016 Results published in the International Clinical Psychopharmacology
    • 06 Mar 2016 Primary endpoint has been met. (Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score), as per an article published in the International Clinical Psychopharmacology.
    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top